Drugs / Personalized tumor peptide vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06314087 | Jan 2024 → Aug 2026 overdue | metastatic neoplasm | The University of Hong Kong-Shenzhen Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Personalized tumor peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06314087 ↗ |
| Modality | Vaccine | “Synthesize tumor neoantigen peptide vaccine based on tumor neoantigen” NCT06314087 ↗ |